The conglomerate chaired by business leader Manuel V. Pangilinan kicked off today its inoculation of 60,000 employees rendering essential work during the pandemic.
Led by the MVP Group Vaccine Task Force, the first tranche of company-procured Moderna doses were administered to the Group’s first batch of employees at Meralco Compound in Pasig.
The launch site is one of several facilities the Group has identified in administering all the vaccinations in the National Capital Region+ (NCR+). Among those to be activated by the second week of July include PLDT Sta. Ana in Manila, Smart Tower in Makati, Maynilad Balara in Quezon City, and NLEX Sta Rita in Bulacan.
PLDT, Smart pilot enhanced Unicef assessment tool
PLDT, Smart launch sustainable development initiatives
“Our vaccinees, through the essential services we offer groupwide — from hospitals, telecommunications and digital services, electricity, water, tollways, and road infrastructure, media, and more — have been and will continue to be the key source of stability as the Philippines emerges from this global crisis,” Pangilinan said.
Vaccine Task Force
Each pilot site, to be manned mainly by frontliners from the Group’s own Metro Pacific Hospitals Holdings Inc. (MPHHI), is expected to vaccinate an average of 700 and up to 1,350 individuals per day.
For areas outside NCR+, the Vaccine Task Force will use a combination of MPHHI’s Philippines-largest private healthcare network, other Group-wide facilities, and selected malls across the country.
The Group previously announced that the MVP Group Vaccine Task Force ordered vaccines from Moderna and Astra Zeneca enough for more than 300,000 employees, dependents and household members, and the Group’s extended workforce.
“Any talk about ending this pandemic begins with a fundamental imperative: the successful rollout of ethically procured, safe, and effective vaccines to a significant majority of our people,” Pangilinan said. “Inoculating the population from the virus does not just reduce the number of infections and deaths — but minimizes the possibility of new mutations and variants, taking us a step closer toward the paramount goal of herd immunity.”
Categories: Media Release